RTI Surgical (RTIX) CEO Hutchison to Retire
- Wall Street falls as bank, healthcare shares weigh
- Qualcomm (QCOM) Faces U.S. Antitrust Case Over Licensing - Bloomberg
- BAT Reaches Deal to Acquire Reynolds American (RAI) for $49 Billion
- Verizon Communications (VZ) May Acquire Big Cable Company - NYP (CHTR) (CMCSA)
- Citron Research Negative on Lannett (LCI); Sees Shares at 'Zero' Over Long Term
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
RTI Surgical Inc. (Nasdaq: RTIX) announced that Brian K. Hutchison has informed the RTI board of directors that he has decided to retire from his position as president and chief executive officer and step down from the board of directors. Hutchison has agreed to remain in his current roles to assist the RTI board and management team with an orderly transition to a new leader. RTI’s board is commencing a search for the chief executive officer position.
“We have asked Brian to remain with us to ensure an orderly transition to a new CEO,” said RTI Chairman Curtis M. Selquist. “On behalf of the entire board, I want to recognize Brian for the many contributions he has made to transforming RTI into a leading global provider of surgical implants. RTI has a strong bench of management talent that I know will continue to lead the company forward as it remains focused on developing and delivering exceptional products and achieving sustainable top- and bottom-line growth.”
“It has been an honor to serve RTI and help it grow into a market leader,” Hutchison said. “I have great confidence in our board and management, and I will work diligently with them during this transition period to help position the company for operational and financial performance over the long term.”
Hutchison joined RTI as president and CEO on Dec. 5, 2001, and oversaw its growth from a small tissue bank in Florida to a leading global player in biologics-based implants. Over the past 15 years, the company has expanded its product portfolio significantly from a few allograft implants used in spinal and orthopedic applications to a multifaceted portfolio of biologic, metals and synthetic products used in a wide array of surgical applications. Through organic growth as well as the acquisitions of Tutogen Medical Inc. in 2008 and Pioneer Surgical Technology in 2013, RTI is now positioned as a solid and respected leader in the donation community and as a well-known innovator of safe, high quality surgical implants to surgeons around the globe. Today, RTI has more than 1,100 employees and four manufacturing facilities dedicated to helping patients worldwide.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Forward Pharma (FWP) Confirms Settlement and License Agreement with Biogen (BIIB)
- RPM International (RPM) Acquires Prime Resins
- Pulmatrix (PULM) Announces Drug Candidate Receives QIDP Designation from FDA
Create E-mail Alert Related CategoriesManagement Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!